Ankylose This! Living with Ankylosing Spondylitis

Friday, February 18, 2005

FDA on COX-2

The committees will discuss the overall benefit to risk considerations (including cardiovascular and gastrointestinal safety concerns) for COX-2 selective nonsteroidal anti-inflammatory drugs and related agents.

Visit Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee. It's running Feb. 16-18, 2005. They invite public participation.
Electronic comments should be submitted to Select "2004N-0559-Overall Benefit to Risk Considerations for COX-2 Selective Nonsteroidal Anti-inflammatory Drugs and Related Agents" and follow the prompts to submit your statement.

I tried to find this docket in their system; I wasn't able to. Maybe you will have better luck.

Comments on this post

Post a Comment

Links to this post

Create a Link